Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Identifying Epigenetic Biomarkers for Prostate Cancer

Published: Tuesday, April 01, 2014
Last Updated: Tuesday, April 01, 2014
Bookmark and Share
IDT qPCR assays and probes facilitate the development of predictive epigenetic biomarkers.

In the latest issue of DECODED, Integrated DNA Technologies (IDT) talks about how the prognosis for men with aggressive forms of prostate cancer is improved if detected early.

Dr Antoinette Perry, Senior Research Fellow at the Institute of Molecular Medicine (Dublin, Ireland) leads a team whose research is directed at understanding how changes in DNA methylation of both coding and non-coding RNA genes are involved in driving prostate carcinogenesis.

Previously published work by Dr Perry revealed that SFRP2, a Wnt signalling agonist, is hypermethylated in approximately 65% of prostate tumors.

IDT PrimeTime® qPCR Assays were used to measure expression levels of SFRP2, and subsequent analysis showed an inverse correlation between expression and tumor grade.

As part of a further investigation into the involvement of hypermethylated genes in prostate cancer, prognostic markers are being developed for use in a non-invasive test that will distinguish high-risk from lower-risk tumors. Following cell recovery, IDT primers and ZEN™ Double-Quenched Probes are used for sensitive quantification of prostate cancer-specific DNA methylation.

In addition to the cellular component, the scientists monitor cell-free nucleic acids for DNA methylation and expression of small non-coding RNAs.

The IDT PrimerQuest (idtdna.com/scitools) is being used to design methylation-specific assays (primers and probes that will hybridize specifically to bisulfite modified methylation target regions, but that will not amplify unconverted genomic DNA or unmethylated DNA).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

IDT's $10 M Expansion Opens Biotech Firm Adds Capacity and Jobs
The new building enables a significant expansion of the company’s HPLC, R&D and production capabilities.
Tuesday, June 27, 2006
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!